[1] Castagna A et al. E-184V study. Lamivudine monotherapy vs treatment interruption in failing HIV-1-infected subjects harbouring the M184V mutation: 48 week final results. Third International AIDS Society Conference on HIV Pathogenesis and Treatment, Rio de Janeiro, abstract WeFo0204, 2005.
[2] Fox Z et al. A randomized trial to evaluate continuation versus discontinuation of lamivudine in individuals failing a lamivudine-containing regimen: the COLATE trial. Antivir Ther 11(6):761-70, 2006.
[3] Masquelier B et al. Identification of genotypic determinants of the virological response to tenofovir-including regimens in nucleoside reverse transcriptase inhibitor-experienced patients. Antivir Ther 7: S105, 2002.
[4] Lo CM et al. Efficacy of tenofovir combination therapy and its genotypic resistance in multifailure HIV-1-infected subjects. Seventh International Congress on Drug Therapy in HIV Infection, Glasgow, abstract P142, 2004.
[5] Landman R et al. Successful rescue therapy in patients developing K65R on tenofovir-containing regimens: long-term follow-up. Twelfth Conference on Retroviruses and Opportunistic Infections, Boston, abstract 710, 2005b.
[6] Liao L et al. HIV drug resistance in treated patients: a national cross-sectional survey in China. Seventeenth International AIDS Conference, Mexico City, abstract TuAA03, 2008.
[7] Hosseinipour M et al. Resistance profile of patients failing first line ART in Malawi when using clinical and immunologic monitoring. Seventeenth International AIDS Conference, Mexico City, abstract TUAB0105, 2008.
[8] Marconi VC et al. Prevalence of HIV-1 drug resistance after failure of a first highly active antiretroviral therapy regimen in KwaZulu Natal, South Africa. Clinical Infectious Diseases 46:1589–1597, 2008.
[9] Orrell C et al. HIV-1 clade C resistance genotypes after first virological failure in a large community ART programme. Ninth International Congress on Drug Therapy in HIV Infection, Glasgow. Abstract O113. 2008.
[10] Shepherd J et al. High levels of class-wide NRTI resistance among HIV-positive patients failing first-line antiretroviral regimens in Nigeria. 2008 HIV Implementers’ Meeting, Kampala, Uganda, abstract 796.
[11] Lu D et al. ARV resistance in patients with treatment failure to first-line regimens in Ho Chi Minh city, Vietnam.Seventeenth International AIDS Conference, Mexico City, abstract TUPDA201, 2008.
[12] Pillay D et al. Emergence and evolution of drug resistance in the absence of viral load monitoring during 48 weeks of Combivir/tenofovir within the DART trial. Fourteenth Conference on Retroviruses and Opportunistic Infections, Los Angeles, abstract 642, 2007.
[13] Macarthur C et al. Survival, plasma HIV-1 RNA concentrations and drug resistance in HIV-1 infected Haitian adolescents and young adults on antiretrovirals. Bulletin of the World Health Organization 86 (12): 970-977, 2008.
[14] Hosseinipour M et al. Clinical, immunological and virological outcomes of second-line treatment, Malawi. Sixteenth Conference on Retroviruses and Opportunistic Infections, Montreal, abstract 605, 2009.
[15] Fox M et al. Clinical outcomes on second-line antiretroviral therapy in a large urban clinic in Johannesburg, South Africa. Sixteenth Conference on Retroviruses and Opportunistic Infections, Montreal, abstract 606, 2009.
[16] Ive P et al. Time from virologic failure to switching to second-line therapy in patients receiving ART in Johannesburg, South Africa.Sixteenth Conference on Retroviruses and Opportunistic Infections, Montreal, abstract 606, 2009.
[17] Ferradini L et al. Efficacy of Kaletra-based second-line ART in Cambodia. Fourteenth Conference on Retroviruses and Opportunistic Infections, Los Angeles, abstract 36LB, 2007.
[18] Pujades-Rodrigues J et al. Second-line antiretroviral therapy in resource-limited settings: the experience of Médecins Sans Frontières AIDS22(11):1305-12, 2008.
[19] Negredo E et al. CD4 cell count changes after reduction of didanosine dosage in patients receiving standard doses of didanosine and tenofovir-based regimens. 44th ICAAC, Washington, abstract H-561, 2004.
[20] Gathe JM et al. Tolerability and therapy preference of lopinavir/ritonavir (Kaletra) soft gel capsules and tablets as single agent in a cohort of HIV-positive adult patients (IMANI-2). Eighth International Congress on Drug Therapy in HIV Infection, Glasgow, 2006.
[21]Hsu A, Granneman GR, Carothers L, et al. Ritonavir does not increase methadone exposure in healthy volunteers. Presented at the 5th conference on retroviruses and opportunistic infections, Chicago, February 1-5, 1998.
[22] Garren KW et al. Bioavailability of generic ritonavir and lopinavir/ritonavir tablet products in a dog model. J Pharmaceutical Sciences, online publication February 10, 2009.
[23] Avihingsanon A et al. A low dose of ritonavir-boosted atazanavir provides adequate pharmacokinetic parameters in HIV-1-infected Thai adults. Clinical Pharmacology & Therapeutics advance online publication 31 December 2008. doi:10.1038/clpt.2008.244
[24] Squires K et al. Comparison of once-daily atazanavir with efavirenz, each in combination with fixed-dose zidovudine and lamivudine, as initial therapy for patients infected with HIV. J Acquir Immune Defic Syndr 36: 1011-1019, 2004.
[25] Malan N et al. Efficacy and safety of atazanavir-based therapy in antiretroviral naïve HIV-1 infected subjects both with and without ritonavir: 96-week results from AI424-089. 4th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention, abstract WEPEB024, Sydney, 2007.
[26] Boyd MA, Srasuebkul P, Ruxrungtham K et al.: Relationship between hyperbilirubinaemia and UDP-glucuronosyltransferase 1A1 polymorphism in adult HIV-infected Thai patients treated with indinavir. Pharmacogenet. Genomics 16(5), 321–329, 2006.
[27] Johnson M et al. Atazanavir plus ritonavir or saquinavir, and lopinavir / ritonavir in patients experiencing multiple virological failures. AIDS 19: 685-694, 2005.
[28] Haubrich R et al. Metabolic outcomes of ACTG 5142: a prospective randomised phase III trial of NRTI, PI- and NNRTI-sparing regimens for initial treatment of HIV-1 infection. Fourteenth Conference on Retroviruses and Opportunistic Infections, Los Angeles, abstract 38, 2007.
[29] McComsey G et al. Changes in body composition with ritonavir-boosted and unboosted atazanavir treatment in combination with lamivudine and stavudine: a 96-week randomized, controlled study. Clin Infect Dis 48:1323–1326, 2009.
[30] Hay P et al. Fewer subjects switching to qd ATV/r have limb fat loss versus those continuing bid PI/r: 96 week results of the multicentre, open-label, randomized, prospective ReAL study for the management of lipodystrophy. HIV Medicine 10 (1): 1-10, 2009.
[31] Flandre P et al. Prognostic failures of virological success in antiretroviral-naïve patients receiving LPV/r monotherapy in the MONARK trial. Eleventh European AIDS Conference, Madrid, abstract PS1/2, 2007.
[32] Cameron W et al. A two-year randomized controlled clinical trial in antiretroviral-naïve subjects using lopinavir/ritonavir (LPV/r) monotherapy after initial induction treatment compared to an efavirenz (EFV) 3-drug regimen (Study M03-613). Sixteenth International AIDS Conference, Toronto, abstract THLB0201, 2006.
[33] Waters L et al. Kaletra monotherapy – a real-life experience. HIV Med 7 (Supplement 1), abstract P9, 2006.
[34] Swindells S et al. A prospective, open-label, pilot trial of regimen simplification to atazanavir/ritonavir alone as maintenance antiretroviral therapy after sustained virologic suppression (ACTG 5201). Thirteenth Conference on Retroviruses and Opportunistic Infections, Denver, abstract 108LB, 2006.
[35] Bannister WP et al. Comparison of genotypic resistance profiles and virological response between patients starting nevirapine and efavirenz in EuroSIDA. AIDS 22: 367-376, 2008.
[36] Ruxrungtham K et al. Impact of reverse transcriptase resistance on the efficacy of TMC125 (etravirine) with two nucleoside reverse transcriptase inhibitors in protease inhibitor-naïve, nonnucleoside reverse transcriptase inhibitor-experienced patients: study TMC125-C227. HIV Medicine 2008 (e-published ahead of print).
[37] Reynolds S et al. Evaluation of the WHO immunologic criteria for ART failure among adults in Rakai, Uganda. Sixteenth Conference on Retroviruses and Opportunistic Infections, Montreal, abstract 144, 2009.